Sažetak
Background: Asthma is characterized by complex immune dysregulation involving coordinated cytokine and chemokine networks. OX40 ligand (OX40L), a key T-cell co-stimulatory molecule, has been implicated in Th2-mediated inflammation; however, its serum-level biochemical interactions with immune activation pathways in asthma remain incompletely defined.
Methods: In this cross-sectional study, serum OX40L and immune activation-related factors were quantified in 82 patients with asthma and 40 healthy controls. Multiplex cytokine analysis was performed to measure Th2-, Th17-, pro- and anti-inflammatory mediators, along with chemokines and total IgE. Lung function indices were assessed by spirometry. Correlation analysis and multivariable linear regression were applied to identify immune factors independently associated with serum OX40L levels.
Results: Serum OX40L concentrations were significantly elevated in asthma patients compared with controls and increased progressively with disease severity (all P<0.001). OX40L exhibited strong positive correlations with Th2-associated cytokines, particularly interleukin-5 (IL-5; r=0.75, P<0.001), and chemokines, while showing a significant inverse association with the anti-inflammatory cytokine IL-10. OX40L levels were also negatively correlated with forced expiratory volume in one second (FEV1%pred; r=-0.72, P<0.001). Multivariable regression identified IL-5 (β=0.35), FEV1%pred (β=-0.28), and annual exacerbation frequency (β=0.22) as independent biochemical determinants of serum OX40L, collectively explaining 68.3% of its variance.
Conclusion: Serum OX40L is closely integrated within the Th2-dominant immune activation network in asthma and reflects both immune imbalance and functional airway impairment. These findings support OX40L as a biochemically relevant indicator of immune activation intensity and highlight its potential role within cytokine-driven regulatory pathways in asthma.
Ključne reči
Array
Array
Array
Array
Reference
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.